Infant Bacterial Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics

EmergingBioTech

Pediatric Medicine

Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in premature infants, with Phase 3 trial results expected in 2026.

AI VisibilityBeta
Overall Score
D36
Category Rank
#80 of 198
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
36
Gemini
36

About

Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#80
Category Rank
#11
88
AI Consensus
68
stable
Trend
stable
32
ChatGPT
71
36
Perplexity
68
36
Gemini
80
36
Claude
77
33
Grok
69

Key Details

Category
Pediatric Medicine
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Infant Bacterial Therapeutics
Pediatric Medicine

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.